Women’s health is widening its scope to midlife

For most of modern healthcare, menopause has been treated as something to simply endure. The symptoms — hot flashes, brain fog, sleep disruption — are familiar and recognized by many. Accessible treatment options and support? Far less so.

That’s starting to change. With an estimated one billion women reaching menopause by 2025 — about 12% of the global population — the gap has become impossible to ignore. The menopause market is projected to grow from $17.79 billion in 2024 to over $24 billion by 2030, and companies are building infrastructure to serve it.

What’s changing

Companies are entering menopause care with different approaches: some are making specialist care and prescriptions easier to access, while others are creating tracking tools to help people understand what’s happening in their bodies.

• Hers launched menopause and perimenopause personalized treatment plans, expanding beyond its existing weight loss and sexual health offerings.
• Midi Health is building an AI search engine for women’s health, tackling the problem of outdated or inaccurate information about menopause online.

• Natural Cycles, known for its FDA-cleared birth control app, added perimenopause tracking to help women understand hormonal shifts across life stages.
• Alloy focuses on evidence-based hormone therapy and education, cutting through the confusion that’s kept many women from pursuing treatment.

The common thread: removing friction. Hormone therapy, lab work, and symptom tracking are now accessible through digital platforms, bypassing barriers like geographic limitations, provider knowledge gaps, and appointment wait times.

Why this matters now

While fertility and pregnancy have historically attracted the most investment in femtech, women in midlife have been largely overlooked. In the United States alone, about 6,000 women enter menopause every day.

In 2024, global femtech investment reached $2.2 billion, and menopause-related ventures have gained strong traction. The failure to address menopause’s impact is conservatively costing the U.S. economy more than $26 billion annually, and companies are starting to recognize what that represents: decades of productive life that deserve support.

What it signals

This shift has the mission of building infrastructure that didn’t exist: accessible hormone therapy, symptom tracking, and clinical support for a medically neglected stage of life.

The question now isn’t whether perimenopause and menopause care will grow. It’s whether the solutions being built are evidence-based, affordable, and designed to last — or just capitalizing on a moment of attention.